BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 20,500 Shares of Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 20,500 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $96.31, for a total value of $1,974,355.00. Following the completion of the sale, the chief executive officer directly owned 688,209 shares of the company’s stock, valued at approximately $66,281,408.79. This trade represents a 2.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total value of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total value of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The stock was sold at an average price of $103.52, for a total value of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $102.85, for a total value of $4,628,250.00.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $96.73 on Friday. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. The stock’s fifty day simple moving average is $96.98 and its two-hundred day simple moving average is $95.38. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The stock has a market cap of $24.46 billion, a PE ratio of -12.35 and a beta of 1.29.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The firm had revenue of $122.31 million during the quarter, compared to the consensus estimate of $180.18 million. During the same quarter in the previous year, the company earned ($1.60) EPS. The business’s revenue was down 59.5% compared to the same quarter last year. As a group, analysts forecast that BioNTech SE Sponsored ADR will post -6.33 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

A number of hedge funds have recently modified their holdings of BNTX. Monaco Asset Management SAM bought a new stake in shares of BioNTech in the fourth quarter valued at $1,594,000. Hsbc Holdings PLC purchased a new position in shares of BioNTech during the 4th quarter valued at $4,969,000. Bank of America Corp DE grew its stake in shares of BioNTech by 22.6% during the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after acquiring an additional 166,432 shares during the period. BNP Paribas Financial Markets grew its stake in shares of BioNTech by 43.0% during the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after acquiring an additional 474,796 shares during the period. Finally, Amundi increased its holdings in BioNTech by 24.5% in the 1st quarter. Amundi now owns 129,513 shares of the company’s stock worth $11,511,000 after acquiring an additional 25,506 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

Analyst Upgrades and Downgrades

BNTX has been the subject of several recent analyst reports. Wall Street Zen lowered BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Jefferies Financial Group reiterated a “buy” rating on shares of BioNTech in a report on Monday, June 1st. Morgan Stanley cut their price objective on BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 8th. Canaccord Genuity Group reduced their price objective on BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Finally, Citigroup decreased their target price on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $126.00.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.